COYA TAPIA to Prognosis
This is a "connection" page, showing publications COYA TAPIA has written about Prognosis.
Connection Strength
0.140
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.050
-
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol. 2004 Dec; 25(6):1551-7.
Score: 0.017
-
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581.
Score: 0.014
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.012
-
Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8.
Score: 0.009
-
Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015 Nov 09; 15:872.
Score: 0.009
-
IMRT with ?8FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol. 2014 Mar 25; 9:83.
Score: 0.008
-
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012 Apr 03; 12:134.
Score: 0.007
-
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007 Jul; 60(7):768-72.
Score: 0.005
-
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004 Dec 01; 64(23):8534-40.
Score: 0.004
-
KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):178-83.
Score: 0.004